MC2096A1 - Pyrroles substitues - Google Patents

Pyrroles substitues

Info

Publication number
MC2096A1
MC2096A1 MC902110A MC2110A MC2096A1 MC 2096 A1 MC2096 A1 MC 2096A1 MC 902110 A MC902110 A MC 902110A MC 2110 A MC2110 A MC 2110A MC 2096 A1 MC2096 A1 MC 2096A1
Authority
MC
Monaco
Prior art keywords
substituted pyrroles
active substances
derivatives
substances
furandione
Prior art date
Application number
MC902110A
Other languages
English (en)
French (fr)
Inventor
David Davis Peter
Huw Hill Christopher
Lawton Geoffrey
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898904161A external-priority patent/GB8904161D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MC2096A1 publication Critical patent/MC2096A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Pyridine Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
MC902110A 1989-02-23 1990-02-16 Pyrroles substitues MC2096A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898904161A GB8904161D0 (en) 1989-02-23 1989-02-23 Substituted pyrroles
GB898928210A GB8928210D0 (en) 1989-02-23 1989-12-13 Substituted pyrroles

Publications (1)

Publication Number Publication Date
MC2096A1 true MC2096A1 (fr) 1991-02-15

Family

ID=26295005

Family Applications (1)

Application Number Title Priority Date Filing Date
MC902110A MC2096A1 (fr) 1989-02-23 1990-02-16 Pyrroles substitues

Country Status (20)

Country Link
EP (1) EP0384349B1 (xx)
JP (1) JPH06102661B2 (xx)
AT (1) ATE104972T1 (xx)
AU (1) AU633051B2 (xx)
CA (1) CA2010636C (xx)
CZ (1) CZ284587B6 (xx)
DE (1) DE59005491D1 (xx)
DK (1) DK0384349T3 (xx)
DZ (1) DZ1399A1 (xx)
ES (1) ES2052995T3 (xx)
FI (1) FI93447C (xx)
HU (1) HU206351B (xx)
IE (1) IE64184B1 (xx)
IL (1) IL93433A (xx)
MC (1) MC2096A1 (xx)
NO (1) NO174891C (xx)
NZ (1) NZ232589A (xx)
PT (1) PT93246B (xx)
RU (2) RU2142460C1 (xx)
SK (1) SK278711B6 (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
JPH07504673A (ja) * 1992-03-20 1995-05-25 ザ・ウエルカム・ファウンデーション・リミテッド 抗ウイルス活性を有するインドール誘導体
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
DE69418978T2 (de) * 1993-12-07 1999-10-28 Eli Lilly And Co., Indianapolis Synthese von Bisindolylmaleimiden
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
PT657458E (pt) * 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
CA2179650C (en) * 1993-12-23 2007-10-30 William Francis Heath, Jr. Bisindolemaleimides and their use as protein kinase c inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
DE69505470T2 (de) * 1994-08-04 1999-05-12 F. Hoffmann-La Roche Ag, Basel Pyrrolocarbazol
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
CN1145623C (zh) * 1994-12-13 2004-04-14 霍夫曼-拉罗奇有限公司 咪唑衍生物
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
ES2212814T3 (es) * 1996-10-31 2004-08-01 Harbor Branch Oceanographic Institution, Inc. Uso de compuestos y composiciones antiinflamatorias neurogenicas.
EP1224932A4 (en) * 1999-08-20 2002-10-16 Sagami Chem Res DRUGS INHIBITING CELL DEATH
CZ2003555A3 (en) 2000-07-27 2004-03-17 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
YU46603A (sh) 2000-12-08 2006-05-25 Ortho-Mcneil Pharmaceutical Inc. Indazolil-supstituisana jedinjenja pirolina, kao inhibitori kinaze
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
WO2005014004A1 (en) 2003-08-08 2005-02-17 Novartis Ag Combinations comprising staurosporines
RU2372348C2 (ru) * 2004-01-19 2009-11-10 Новартис Аг Производные индолилмалеимида в качестве ингибиторов ркс
US8008320B2 (en) 2004-12-08 2011-08-30 Johannes Gutenberg-Universitatis 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
CN101941970B (zh) 2005-02-09 2013-08-21 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
ES2396671T3 (es) 2005-07-11 2013-02-25 Novartis Ag Derivados de la indolilmaleimida como inhibidores de la proteína quinasa
CA2618550C (en) * 2005-08-12 2013-12-17 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
EP1980561B1 (en) 2007-03-30 2013-10-09 Nerviano Medical Sciences S.R.L. Substituted 1h-pyrazolo[3,4-b] pyridine derivatives active as kinase inhibitors
WO2009002807A2 (en) 2007-06-22 2008-12-31 Arqule, Inc. Indolyl pyrrolidines for the treatment of cancer
EP2170870B1 (en) * 2007-06-22 2014-03-05 ArQule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
KR20100024494A (ko) 2007-06-22 2010-03-05 아르퀼 인코포레이티드 퀴나졸리논 화합물 및 이의 사용 방법
JP2012502927A (ja) 2008-09-22 2012-02-02 メルク カナダ インコーポレイテッド Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
RU2660417C2 (ru) * 2013-04-23 2018-07-06 Лабораторьос Дель Др. Эстеве, С.А. СОЕДИНЕНИЯ ПИРАЗИНО[1,2-а]ИНДОЛА, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ЛЕКАРСТВЕННЫХ СРЕДСТВАХ
WO2016008966A1 (en) 2014-07-17 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278989B6 (sk) * 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
EP0350129A1 (en) * 1988-07-07 1990-01-10 Duphar International Research B.V New annelated indoleketones with an imidazolylalkyl substituent

Also Published As

Publication number Publication date
JPH06102661B2 (ja) 1994-12-14
SK85590A3 (en) 1998-01-14
AU633051B2 (en) 1993-01-21
IE900647L (en) 1990-08-23
FI93447C (fi) 1995-04-10
CZ85590A3 (cs) 1998-10-14
IL93433A (en) 1996-11-14
IL93433A0 (en) 1990-11-29
NO174891C (no) 1994-07-27
RU2142460C1 (ru) 1999-12-10
DK0384349T3 (da) 1994-09-05
NO900855L (no) 1990-08-24
HU206351B (en) 1992-10-28
PT93246A (pt) 1990-08-31
DZ1399A1 (fr) 2004-09-13
EP0384349A1 (de) 1990-08-29
ATE104972T1 (de) 1994-05-15
JPH02264776A (ja) 1990-10-29
AU5003390A (en) 1990-08-30
EP0384349B1 (de) 1994-04-27
IE64184B1 (en) 1995-07-12
DE59005491D1 (de) 1994-06-01
FI93447B (fi) 1994-12-30
ES2052995T3 (es) 1994-07-16
NO174891B (no) 1994-04-18
FI900863A0 (fi) 1990-02-21
PT93246B (pt) 1996-01-31
RU2014332C1 (ru) 1994-06-15
HUT53369A (en) 1990-10-28
NO900855D0 (no) 1990-02-22
CA2010636A1 (en) 1990-08-23
CA2010636C (en) 1999-12-14
NZ232589A (en) 1992-09-25
CZ284587B6 (cs) 1999-01-13
SK278711B6 (sk) 1998-01-14
HU900846D0 (en) 1990-04-28

Similar Documents

Publication Publication Date Title
MC2096A1 (fr) Pyrroles substitues
FI96204C (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
RU93033479A (ru) Способ получения замещенных пирролов, способ получения фармацевтических препаратов
CA2107105A1 (en) Heterocyclic-cyclic amine derivatives
DE3880047D1 (de) Zusammensetzung eines zusatzes.
NO924598D0 (no) Fremstilling av substituerte piperidiner
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
FI881609A0 (fi) Dihydropyridinamider, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
ATE92469T1 (de) Neue alpha-aminocarbonsaeure-derivate, ihre herstellung und verwendung.
DE3851979D1 (de) Substituierte Vinylcephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
ATE92070T1 (de) Azachromanderivate.
FI906162A (fi) Foerfarande foer framstaellning av 3-(n-metyl-n-alkyl)-amino-2-metoximetylenpropan-1-olderivat.
DK0418990T3 (da) 13-brom- og 13,14-dibrom-ergoliner, deres fremstilling og anvendelse i lægemidler
NO880405D0 (no) Fremgangsmaate til fremstilling av 3-fenyl-7h-tiazolo-/3,2-b//1,2,4/-tiazine-7-oner.
NO305556B1 (no) Tiokarbamoylforbindelser og anvendelse derav samt middel for beskyttelse av tekniske materialer
NO883381D0 (no) Fremgangsmaate ved fremstilling av n-((4-hydrosy-pyrrolidin-2-on-1-yl)-acetyl)-glycinamid.
NO905569L (no) Fremgangsmaate for fremstilling av fettsyrehalogenider.
NO931072L (no) Fremgangsmaate for fremstilling av polyhydraksyfettsyreamider i naervaer av loesningsmiddler

Legal Events

Date Code Title Description
YP Annual fee paid
YP Annual fee paid